doi:10.19982/j.issn.1000-6621.20260340

Abstract

CLC Number:

R521

Figures/Tables 4

References 19

[1]	中华医学会结核病学分会. 抗结核药物超说明书用法专家共识(2023年更新版)[J]. 中华结核和呼吸杂志, 2023, 46(11):1085-1102. doi:10.3760/cma.j.cn112147-20230809-00062.
[2]	中国医药信息查询平台. 异烟肼 [EB/OL]. [2026-06-01]. https://www.dayi.org.cn/drug/1152021.html.
[3]	中国防痨协会药学专业分会. 抗结核药治疗药物监测临床应用专家共识(2025年更新版)[J]. 结核与肺部疾病杂志, 2026, 7(2):131-151. doi:10.19983/j.issn.2096-8493.20262003.
[4]	张亚平, 李尚林. 急性重度异烟肼中毒9例救治分析[J]. 临床合理用药杂志, 2011, 4(19):62-63. doi:10.3969/j.issn.1674-3296.2011.19.046.
[5]	李雅君, 张泰昌. 大剂量异烟肼中毒致癫痫持续状态抢救成功一例[J]. 中华内科杂志, 1994, 33(1):53.
[6]	黄龙全, 张剑韵. 植物维生素B6从头合成与代谢转换研究进展[J]. 西北植物学报, 2015, 35(10): 2124-2131. doi:10.7606/j.issn.1000-4025.2015.10.2124.
[7]	Sankar J, Chauhan A, Singh R, et al. Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement[J]. Front Pharmacol, 2024, 15: 1441147. doi:10.3389/fphar.2024.1441147.
[8]	中国医疗保健国际交流促进会急诊医学分会, 北京医院国家老年医学中心, 中华医学会急诊医学分会. 血乳酸在急危重症应用的急诊专家共识[J]. 中华急诊医学杂志, 2025, 34(10): 1352-1362. doi:10.3760/cma.j.cn114656-20250810-00570.
[9]	陈敏, 张伶俐, 全淑燕, 等. 维生素B6临床应用的安全性评价[J]. 中国药学杂志, 2016, 51(1): 65-69. doi:10.11669/cpj.2016.01.017.
[10]	中国医药信息查询平台. 维生素B6 [EB/OL]. [2026-06-01]. https://www.dayi.org.cn/drug/1154691.html.
[11]	首都医科大学附属北京胸科医院,《中国防痨杂志》编辑委员会. 结核病患者N-乙酰基转移酶2编码基因多态性检测与异烟肼合理用药专家共识[J]. 中国防痨杂志, 2021, 43(11): 1107-1112. doi:10.3969/j.issn.1000-6621.2021.11.001.
[12]	Rao P S, Reed K, Modi N, et al. Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB[J]. IJTLD Open, 2024, 1(2): 90-95. doi:10.5588/ijtldopen.23.0361. pmid: 38655375
[13]	Kodadek L, Carmichael Ii S P, Seshadri A, et al. Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document[J]. Trauma Surg Acute Care Open, 2022, 7(1): e000836. doi:10.1136/tsaco-2021-000836.
[14]	中国抗癌协会肿瘤营养专业委员会, 中国肠外肠内营养学分会. 肿瘤患者再喂养综合征专家共识[J]. 肿瘤代谢与营养电子杂志, 2023, 10(5): 616-618. doi:10.16689/j.cnki.cn11-9349/r.2023.05.008.
[15]	中华医学会肠外肠内营养学分会. 中国成人患者肠外肠内营养临床应用指南(2023版)[J]. 中华医学杂志, 2023, 103(13): 946-974. doi:10.3760/cma.j.cn112137-20221116-02407.
[16]	田子钊, 周晨希, 周伟, 等. 通过时间基因表达谱分析探究异烟肼引起肝损伤的机制[J]. 遗传, 2022, 44(6): 501-509. doi:10.16288/j.yczz.22-069.
[17]	中国民族卫生协会重症代谢疾病分会, 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)[J]. 中国实用内科杂志, 2023, 43(6): 461-480. doi:10.19538/j.nk2023060106.
[18]	Uhlig T, Karoliussen L F, Sexton J, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study[J]. Clin Rheumatol, 2022, 41(12): 3817-3823. doi:10.1007/s10067-022-06416-4.
[19]	《基于药代动力学的临床常见药物急性中毒血液净化治疗共识》专家组. 基于药代动力学的临床常见药物急性中毒血液净化治疗共识[J]. 中国全科医学, 2025, 28(9): 1033-1043. doi:10.12114/j.issn.1007-9572.2024.0514.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Pengfei, Xiao Yu, Xiong Yanjun, Liang Yaxue, Wang Hua, Zhao Dahai. Impact of nutritional status on early efficacy and adverse drug reactions in patients with drug-resistant pulmonary tuberculosis and construction of a risk scoring model [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1561-1570.
[2]	. [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1659-1664.
[3]	Ding Guangzhao, Zhao Liping, Wu Zhuoran, Wu Xueting, Liu Rongmei. A single-center retrospective analysis of treatment course characteristics and duration distribution in inpatients with lymph node tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1612-1617.
[4]	Lu Fengyue, Su Biyi, Zhao Wei, Guan Ping, Zhu Jialou, Tan Yaoju. Application value of TB-RNA in early effectiveness evaluation of anti-tuberculosis treatment in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1597-1603.
[5]	Xiang Jingling, Li Rong, Wang Furong, Tong Dongyi, Nie Wenjuan, Pang Yu. Assessment of depressive, anxious, and insomnia symptoms in patients with rifampicin-resistant pulmonary tuberculosis receiving a pretomanid-containing short-course regimen [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1531-1537.
[6]	Su Dahong, Li Xiaoli, Yang Bin, Shi Yiheng, Lin Weibing, Miao Tiantian, Zhao Jinfeng, Ma Shang, Huo Fengmin, Wang Guirong. Analysis of drug resistance to bedaquiline, delamanid and linezolid in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1523-1530.
[7]	Li Rong, Wang Hua, Zhang Xuejue, Jin Long, Rukeyamu Abudushalamu, Jin Xiuye, Jing Yangfei, Yang Hong, Wu Yanqin, Ren Fei, Nie Wenjuan. Research on the safety of the B-Pa-L/M regimen in the treatment of rifampicin-resistant pulmonary tuberculosis in elderly patients (≥65 Years) [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1515-1522.
[8]	Huang Pengfei, Xiao Yu, Peng Yi, Xiong Yanjun, Guo Shanshan, Nadila Abulizi, Malipati Aierkenjiang, Wang Hua, Rukeyamu Abudushalamu. Efficacy and safety of 6-month short-course regimen B-Pa-L/M versus 18-month long-course regimen for treating rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1506-1514.
[9]	Jiang Wenxin, Zhang Xiangrong, Tang Peijun, Qin Zhihua, Gao Chunjing, Zhang She, Zhao Xinguo, Zhu Limei, Liu Qiao. Safety analysis of the B-Pa-L/M regimen for rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1487-1496.
[10]	Nie Wenjuan, Zhang Mingyue, Zhang Yungui, Rukeyamu·Abudushalamu , Xu Bing, Jin Long, Liang Ruixia, Wang Furong, Xiong Yu, Cui Junwei, Yi Hengzhong, Zhang Fan, Li Hongzhi, Cao Xuegang, Qiu Lei, Bao Zhijian, Wang Guangming, Zhang Fan, Song Yanan, Zhang Haiqin, Chu Naihui, Cheng Shiming. A 6-month short-course regimen for rifampicin-resistant pulmonary tuberculosis in China: a nationwide multicenter single-arm clinical trial [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1480-1486.
[11]	Liu Zhenguo, Xing Wu, Ling Jie, Yao Shanhu, Bai Liqiong, Rong Pengfei. Chest imaging combined with artificial intelligence for standardized tuberculosis screening: implementation bottlenecks and optimization strategies [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1471-1479.
[12]	Ren Feilin, Jin Meihua, Tong Zhaowei, Zheng Pingming. Interpretation of the Group Standard Specifications for the Construction of Tuberculosis Preventive Treatment Clinics in Primary Medical Institutions [J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1259-1265.
[13]	Bai Yan, Chen Yu, Gao Xusheng, Liang Jianqin, Zeng Yi, Wang Yun, Fan Lin. Analysis of clinical characteristics and factors influencing outcomes in elderly patients with drug-susceptible pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1266-1276.
[14]	Xu Chaoyan, Wei Jiaojiao, Li Shanshan, Yao Lin, Li Ling, Gao Mengqiu. Construction and clinical evaluation of an early diagnostic model for Mycobacterium intracellulare pulmonary disease [J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1290-1299.
[15]	Zhang Aihua, Xu Meng, Yang Yuying, Su Shuang, Song Lei, Ma Dandan, Wei Suxia, Cheng Junwei, Fu Chaohong. Analysis of the incidence of anemia and related risk factors in 878 AIDS patients with tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1307-1314.